Recent Insights on the Role of PPAR-β/δ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy.

Neuromolecular Medicine
Anna K StrosznajderJoanna B Strosznajder

Abstract

Peroxisome proliferator-activated receptor (PPAR) β/δ belongs to the family of hormone and lipid-activated nuclear receptors, which are involved in metabolism of long-chain fatty acids, cholesterol, and sphingolipids. Similar to PPAR-α and PPAR-γ, PPAR-β/δ also acts as a transcription factor activated by dietary lipids and endogenous ligands, such as long-chain saturated and polyunsaturated fatty acids, and selected lipid metabolic products, such as eicosanoids, leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Together with other PPARs, PPAR-β/δ displays transcriptional activity through interaction with retinoid X receptor (RXR). In general, PPARs have been shown to regulate cell differentiation, proliferation, and development and significantly modulate glucose, lipid metabolism, mitochondrial function, and biogenesis. PPAR-β/δ appears to play a special role in inflammatory processes and due to its proangiogenic and anti-/pro-carcinogenic properties, this receptor has been considered as a therapeutic target for treating metabolic syndrome, dyslipidemia, carcinogenesis, and diabetes. Until now, most studies were carried out in the peripheral organs, and despite of its presence in brain cells and in different brain regi...Continue Reading

References

Jan 1, 1988·Molecular Neurobiology·A T Campagnoni, W B Macklin
Jun 1, 1980·Neurochemical Research·J Strosznajder, K Domańska-Janik
Sep 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·G DeanD Saffer
Dec 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Toshiya TanakaJuro Sakai
Dec 15, 2006·The Journal of Pharmacology and Experimental Therapeutics·Akinori IwashitaNobuya Matsuoka
Nov 27, 2007·FEBS Letters·Shannon M Reilly, Chih-Hao Lee
Apr 4, 2008·Journal of Neurochemistry·Rajnish K Chaturvedi, M Flint Beal
Dec 2, 2008·PPAR Research·David Bishop-Bailey, Karen E Swales
Jan 7, 2009·Therapeutic Advances in Cardiovascular Disease·Massimo CollinoChristoph Thiemermann
Jul 21, 2009·Pharmacology & Therapeutics·David Bishop-Bailey, Jonas Bystrom
Feb 24, 2010·The Journal of Pharmacology and Experimental Therapeutics·Irene PaternitiSalvatore Cuzzocrea
Mar 5, 2011·British Journal of Pharmacology·Cris S ConstantinescuBruno Gran
Apr 1, 2011·British Journal of Pharmacology·Jihan Youssef, Mostafa Badr
Oct 6, 2011·Journal of Neuroinflammation·Bianca Weinstock-GuttmanMurali Ramanathan
Nov 29, 2011·Antioxidants & Redox Signaling·Karen SchmittAnne Eckert
Dec 14, 2011·The New England Journal of Medicine·Claudia F LucchinettiRichard M Ransohoff
Feb 1, 2013·Annals of Nutrition & Metabolism·Hiroki SuganumaToshiaki Shimizu
Mar 20, 2013·Biochimica Et Biophysica Acta·Emma BarrosoManuel Vázquez-Carrera

❮ Previous
Next ❯

Citations

Aug 1, 2021·Clinical and Experimental Immunology·Wissam BeainoAlbert D Windhorst
Aug 17, 2021·Pediatric Neurology·Nina F Schor, Diana W Bianchi

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
transgenic

Related Concepts

Related Feeds

Alzheimer's Disease: Transcription

Impaired transcription is associated with the pathogenesis and progression of conditions such as Alzheimer's disease (AD). Here are the latest discoveries pertaining to transcription and AD.